申请人:Synaptic Pharmaceutical Corporation
公开号:US05866579A1
公开(公告)日:1999-02-02
This invention is directed to novel imidazole and imidazoline derivatives which are selective agonists for cloned human .alpha..sub.2 adrenergic receptors. This invention is also related to the use of these compounds for the treatment of any disease where modulation of the .alpha..sub.2 receptors may be useful. The invention further provides for a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
本发明涉及新型咪唑和咪唑啉衍生物,它们是选择性激动剂,用于克隆的人类α2肾上腺素受体。本发明还涉及使用这些化合物治疗任何需要调节α2受体的疾病。该发明还提供了一种药物组合物,包括上述定义的化合物的治疗有效量和药用载体。